Studies Of Autoantibodies Against The IC53 Gene In Heart Failure

Backgroud Heart failure is now recognised as a major and escalating public health problem in industrialised countries with ageing popu- lations.Congestive heart failure (CHF) is a complex clinical disorder resulting from any structural insult causing cardiac dysfunction and associated with hemodynamic abnormalities, such as inadequate cardiac output, abnormal vascular resistance, and elevated ventricular filling pressures.Our understanding of the pathogenesis of chronic heart failure has evolved from a "defective pump" to the persistent overactivation of various compensatory systems of hormones. Supportive evidence stems from the fact that partial blockade of the renin-angiotensin system and adrenergic system leads to improved survival.In addition to those systems, it is now clear that in the CHF state, activation of the inflammatory system occurs, resulting in the production and release of proinflammatory cytokines, activation of the complement system, production of autoantibodies,and overexpression of class II major histocompatibility complex molecules as well as adhesion molecules that may perpetuate the inflammatory state. Recognition of this new pathway of activation in CHF has led to the investigation of new therapies aimed to block, modify, or prevent the inflammatory state.Objective To determine whether the antibody against the IC53 gene is related to CHF resulting from different cardiac diseases .Methods (1)We studied 188 congetive heart failure patients who underwent therapy from June in 2004 to June in 2005 in Shandong Provinical Hospital and 166...